[Increased risk of osteoporosis in thyroid hormone substitution therapy].
Prolonged substitution treatment with thyroid hormones can be one of the causes of osteoporosis. Preliminary results indicate that the risk of the enhanced loss of bone mass in these patients could be apparent from the biochemical indicator of bone reabsorption (urinary hydroxyproline excretion).
Límanová
Z
Z
III. interní katedra fakulty vseobecného lékarství Univerzity Karlovy, Praha.
Stĕpán
J
J
D000368:Aged; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000139:chemically induced*; D012307:Risk Factors; D013963:Thyroid Hormones / Q000009:adverse effects* / Q000627:therapeutic use; D013964:Thyroid Neoplasms / Q000188:drug therapy / Q000652:urine
D013963:Thyroid Hormones; D006909:Hydroxyproline
Zvýsené riziko osteoporózy pri substitucní lécbĕ tyreoidálními hormony.